Joint WFH-ISTH session: Issues in clinical trial design

Haemophilia

Volumn 20, Issue S4, 2014, Pages 137-144

  Peyvandi, F ^a   Farrugia, A ^b   Iorio, A ^c   Key, N S ^d   Srivastava, A ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Clinical trials; Haemophilia; Regulatory requirements

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR CONCENTRATE; FIBRINOGEN CONCENTRATE; NEUTRALIZING ANTIBODY; OPIATE; ROSIGLITAZONE; THALIDOMIDE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ANALYTIC METHOD; AWARENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INCIDENCE; LABORATORY TEST; LONG TERM CARE; MEDICAL TECHNOLOGY; PATIENT MONITORING; PATIENT SAFETY; PERSONALIZED MEDICINE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; BLOOD COAGULATION DISORDERS, INHERITED; METHODOLOGY; TREATMENT OUTCOME;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84899561580     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12415     Document Type: Review

References (60)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
2. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-15.
3. Raut S SMIA: A new approach in FVIII inhibitor measurement and standardization. 58th Annual SSC, 2012.
4. Powell JS, Josephson NC, Quon D et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.
5. Tiede A, Brand B, Fischer R et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
6. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009 Committee for medicinal products for human use (CHMP). Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf. Accessed July 21, 2011.
7. Lee ML, Roth DA. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia 2005; 11: 5-12.
8. Gouw SC, van der Bom JG, Ljung R et al. PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
9. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII: C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 1988; 71: 344-8.
10. Farrugia A. The regulatory pendulum in transfusion medicine. Transfus Med Rev 2002; 16: 273-82.
11. Food and Drug Administration. Summary Basis for Regulatory Action - Treatment of acute bleeding in patients with congenital fibrinogen deficiency, afibrinogenemia and hypofibrinogenemia [Internet]. 2009. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM244507.pdf. Accessed November 25, 2013.
12. De Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 2012; 32: 153-64.
13. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669-76.
14. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2-8.
15. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl 4): 131-5.
16. Gerss JWO, Köpcke W. Clinical trials and rare diseases. Adv Exp Med Biol 2010; 686: 173-90.
17. Farrugia A. Trialing plasma protein therapies for rare disorders: thinking outside the box. Pharm Policy Law 2009; 11: 345-52.
18. Temple RJ. The regulatory pathway for rare diseases lessons learned from examples of clinical study designs for small populations [Internet]. 2013. Available at: http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm352759.pdf. Accessed November 18, 2013.
19. Committee for medicinal products for human USE, (CHMP). guideline on clinical trials in small populations [Internet]. 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf. Accessed November 18, 2013.
20. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011; 8: 161-73.
21. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future. Milbank Q 2008; 86: 533-55.
22. Scuffham PA, Nikles J, Mitchell GK et al. Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med 2010; 25: 906-13.
23. Valentino LA, Ismael Y, Grygotis M. Novel drugs to treat hemophilia. Expert Opin Emerg Drugs 2010; 15: 597-613.
24. Mannucci PM. Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management. Haemophilia 2013; 19: 344-8.
25. Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol 2010; 63: 1312-23.
26. Haynes B, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; CD000011.
27. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β-adrenergic receptor agonists. Pediatrics 2011; 128: e1147-54.
28. Buckeridge D, Huang A, Hanley J et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc 2010; 58: 1664-70.
29. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010; 170: 1968-76.
30. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise BMJ 2007; 334: 349-51.
31. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-8.
32. Peerlink K, Arnout J, Gilles G, Saint-Remy J-M, Vermylen J. A Higher than Expected Incidence of Factor VIII Inhbitors in Multitransfused Haemophilia A Patients Treated with Intermediate Purity Pasteurized factor VIII Concentrate. Thromb Haemost 1993; 69: 115-18.
33. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005; 95(Suppl 1): S144-50.
34. Tugwell P, Haynes B. Assessing claims of causation. In: Haynes RB, Sackett DL, Guyatt GH, Tugwell P eds. Clinical epidemiology: how to do clinical practice research. Philadelphia, PA: Lippincott, Williams and Wilkins, 2006: 356-387.
35. EMA. Guideline on clinical investigation of recombinant and human plasma-derived factor VIII products. 2011. EMA/CHMP/BPWP/144533/2009.
36. EMA. Guideline on clinical investigation of recombinant and human plasma-derived factor IX products. 2011.
37. Colvin BT, Hay CR, Hill FG, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor working party. United Kingdom haemophilia centre directors organization. Br J Haematol 1995; 89: 908-10.
38. Darby SC, Keeling DM, Spooner RJD et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
39. Hay CRM, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
40. Darby SC, Kan SW, Spooner RJ et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
41. Giles A, Rivard G, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
42. Nagel K, Walker I, Decker K, Chana KC, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia 2011; 17: 872-4.
43. Webert KE, Rivard GE, Teitel J et al. Low prevalence of inhibitor antibodies in the Canadian haemophilia population. Haemophilia 2012; 18: e254-9.
44. Walker I, Pai M, Akabutu J et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-51.
45. Rubinger M, Lillicrap D, Rivard GE et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-6.
46. Iorio A, Oliovecchio E, Morfini M, Mannucci PM, On PMM, Of B. Italian registry of haemophilia and allied disorders. objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
47. Tagliaferri A, Rivolta GF, Iorio A et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
48. Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfus 2010; 9: 60-9.
49. Giampaolo A, Abbonizio F, Puopolo M et al. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med 2011; 21: 280-4.
50. Tagariello G, Iorio A, Santagostino E et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency : an index of different clinical severity of the 2 coagulation disorders Comparison of the rates of joint arthroplasty in patients with severe factor VIII. Blood 2009; 114: 779-84.
51. Tagariello G, Iorio A, Matino D et al. High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia a patients not undergoing immunotolerance. J Hematol Oncol 2013; 6: 63.
52. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-81.
53. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia 2012; 18: 276-83.
54. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010; 38: S475-81.
55. Carpenter SL, Michael Soucie J, Sterner S, Presley R. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia 2012; 18: e260-5.
56. Makris M, Calizzani G, Fischer K et al. EUHASS: the european haemophilia safety Surveillance system. Thromb Res 2011; 127: S22-5.
57. Gouw SC, van den Berg HM, Fischer K et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-55.
58. Gouw S, van den Berg M, van der Bom JG. Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the RODIN study. Haemophilia 2012; 18: 1-208.
59. Dimichele DM, Blanchette V, Berntorp E. Clinical trial design in haemophilia. Haemophilia 2012; 18(Suppl 4): 18-23.
60. Marcucci M, Cheng J, Oldenburg J et al. Meta-analysis of Post Authorization Safety Studies: worldwide postmarking surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method rAHF-PFM. J Thromb Haemost 2013; 11: 1075.